Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma

GENE THERAPY · Published 2026-02-14 · DOI 10.1038/s41434-026-00592-7

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41434-026-00592-7

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Applications of genome editing technologies in the treatment of human diseases · GENE THERAPY · 2026 · Same journal
• Ultrasound-guided left heart injection: a safer and more efficient strategy for mouse thoracic aortic gene delivery · GENE THERAPY · 2026 · Same journal
• Optimization and scale up strategies for reproducible AAV enrichment step on CIMmultus® QA HR line · GENE THERAPY · 2026 · Same journal
• Antimicrobial resistance and gene therapy: emerging molecular strategies for a global health threat · GENE THERAPY · 2026 · Same journal
• AAV2 capsid clearance and neuronal trafficking dynamics in the central nervous system · GENE THERAPY · 2026 · Same journal
• Precision rewriting of muscle genetics: therapeutic horizons of base and prime editing in skeletal muscle disorders · GENE THERAPY · 2025 · Same journal
• rAAV8 encapsidated HMR-001/z enables high efficiency hepatic transduction and restores hemostasis in hemophilic mice · GENE THERAPY · 2026 · Same journal
• In vitro and in vivo rescue of dopaminergic neurons in Parkinson’s disease models after Parkin gene therapy · GENE THERAPY · 2026 · Same journal
• Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice · GENE THERAPY · 2026 · Same journal
• Therapeutic in vivo genome editing: innovations and challenges in rAAV vector-based CRISPR delivery · GENE THERAPY · 2025 · Same journal